Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

This study has suspended participant recruitment.
(Protocol being amended to include new data on optimum CD3 dose.)
Sponsor:
Collaborator:
Miltenyi Biotec, Inc.
Information provided by (Responsible Party):
William P. Vaughan, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00959140
First received: August 12, 2009
Last updated: June 18, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: October 2014
  Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)